Wimbledon 2024 is just days away, and ODT website visitors marked the occasion appropriately this past week, overwhelmingly favoring Smith+Nephew’s announcement about sponsoring Wimbledon players. The company is sponsoring championship players this year in order to spotlight its advanced Sports Medicine portfolio. 

Personnel and product innovation news proved popular this past week too. Moximed and Orthofix both fueled website visits with their respective new leadership changes—Moximed named Christopher Gleason as CEO and Orthofix appointed Acera Surgical CEO Michael Finegan as board chairman. 

Ricoh USA, Stratasys, and Axogen, meanwhile, attracted cybervisitors with the scoop about their new technologies. Ricoh USA and Stratasys gained followers by announcing the start of a clinical study to assess the use of 3D-printed models for orthopedic oncology. The patient-specific, 3D-printed anatomical models will be evaluated for preoperative planning and tumor excision compared to solely CT or MRI imaging. The joint research’s goal is to show improvements in surgical outcomes like reduced blood loss, shorter operating time including time under anesthesia, and lowered procedural complication risk.

Axogen, on the other hand, drove traffic by launching the Avive+ Soft Tissue Matrix, intended for use as a soft tissue barrier. Avive+ is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. Avive+ is processed and distributed in accordance with U.S. Food and Drug Administration (FDA) requirements for Human Cellular and Tissue-based Products (HCT/P) under 21 CFR Part 1271 regulations, U.S. State regulations as a 361 human tissue product.
 

1. Smith+Nephew Sponsors Wimbledon Players

2. Moximed Names Christopher Gleason as Chief Exec

3. Ricoh USA, Stratasys Begin Study to Assess 3D Printed Models for Orthopedic Tumor Removal

4. Orthofix Names New Board Chairman

5. Axogen Releases Avive+ Soft Tissue Matrix